Palliative & End-of-Life DistressDepressive DisordersAnxiety DisordersDMTKetamineSalvia Divinorum

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

This large-scale data-analytic study compared the semantic similarity of psychoactive trip reports (n≈15,000) and narrative accounts Near-Death Experiences (n=625), and found that ketamine (followed by salvinorin A and DMT) bared the most resemblance to the experience of 'dying'. The authors speculate that a ketamine model of Near-Death Experiences may indicate a neuroprotective function of endogenous NMDA antagonists released in the proximity of death.

Authors

  • Enzo Tagliazucchi
  • Claudio Pallavicini
  • Fire Erowid

Published

Consciousness and Cognition
individual Study

Abstract

Introduction

The real or perceived proximity to death often results in a non-ordinary state of consciousness characterized by phenomenological features such as the perception of leaving the body boundaries, feelings of peace, bliss and timelessness, life review, the sensation of traveling through a tunnel and an irreversible threshold. Near-death experiences (NDEs) are comparable among individuals of different cultures, suggesting an underlying neurobiological mechanism. Anecdotal accounts of the similarity between NDEs and certain drug-induced altered states of consciousness prompted us to perform a large-scale comparative analysis of these experiences.

Methods

After assessing the semantic similarity between ≈15,000 reports linked to the use of 165 psychoactive substances and 625 NDE narratives, we determined that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine consistently resulted in reports most similar to those associated with NDEs. Ketamine was followed by Salvia divinorum (a plant containing a potent and selective κ receptor agonist) and a series of serotonergic psychedelics, including the endogenous serotonin 2A receptor agonist N,N-Dimethyltryptamine (DMT).

Results

This similarity was driven by semantic concepts related to consciousness of the self and the environment, but also by those associated with the therapeutic, ceremonial and religious aspects of drug use.

Discussion

Our analysis sheds light on the longstanding link between certain drugs and the experience of “dying“, suggests that ketamine could be used as a safe and reversible experimental model for NDE phenomenology, and supports the speculation that endogenous NMDA antagonists with neuroprotective properties may be released in the proximity of death.

Available with Blossom Pro

Research Summary of 'Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports'

Introduction

Near-death experiences (NDEs) are recurrent, cross-cultural non-ordinary states of consciousness reported in situations of real or perceived proximity to death; common features include out-of-body experiences (OBEs), feelings of peace or bliss, timelessness, life review, tunnel-like travel and passing an irreversible threshold. Previous experimental and anecdotal work has pointed to phenomenological overlaps between NDEs and certain drug-induced altered states, notably with ketamine (an NMDA receptor antagonist) and serotonergic psychedelics such as DMT, but prior studies have been limited by small samples, constrained drug selections and reliance on structured questionnaires. Martial and colleagues set out to address three related questions: whether drugs from particular pharmacological classes yield subjective reports most similar to NDE narratives; whether such similarity can be inferred from unstructured free-text reports using natural language processing; and how heterogeneity in NDE circumstances (cause of loss of consciousness, proximity to death, emotional valence) affects similarity with drug-induced states. To answer these, they retrospectively compared 625 NDE narratives with over 15,000 Erowid reports spanning 165 psychoactive substances across multiple pharmacological classes, using latent semantic analysis (LSA) and other dimensionality-reduction techniques to quantify semantic similarity between written reports.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (30)

Papers cited by this study that are also in Blossom

Efficacy and safety of ketamine in bipolar depression: A systematic review

Alberich, S., Martínez-Cengotitabengoa, M., López, P. et al. · Revista de Psiquiatría y Salud Mental (2017)

1 cited
113 cited
A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010

Barker, S., McIlhenny, E. H., Strassman, R. J. · Drug Testing and Analysis (2012)

Classic hallucinogens and mystical experiences: phenomenology and neural correlates

Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)

A window into the intoxicated mind? Speech as an index of psychoactive drug effects

Bedi, G., Cecchi, G. A., Slezak, D. F. et al. · Neuropsychopharmacology (2014)

89 cited
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

Therapeutic infusions of ketamine: do the psychoactive effects matter?

Dakwar, E., Anerella, C., Hart, C. L. et al. · Drug and Alcohol Dependence (2014)

Show all 30 references
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity

Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

68 cited
Psychedelic Drugs in Biomedicine

Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)

Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)

427 cited
N,N-dimethyltryptamine and the pineal gland: Separating fact from myth

Nichols, D. E. · Journal of Psychopharmacology (2017)

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression

Niciu, M. J., Shovestul, B. J., Jaso, B. A. et al. · Journal of Affective Disorders (2018)

Effects of Schedule I drug laws on neuroscience research and treatment innovation

King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)

Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions

Riva-Posse, P., Reiff, C. M., Edwards, J. A. et al. · Journal of Affective Disorders (2018)

Acute Biphasic Effects of Ayahuasca

Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)

101 cited
Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

DMT models the near-death experience

Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)

Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)

89 cited

Cited By (6)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.